Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic CancerCraig M. Goodwin, Channing J. Der, Autumn J. McRee et al.|Cancer Research|2022Cited by 160
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation MappingJulia Wulfkuhle, Emanuel F. Petricoin, Daniela Berg et al.|Clinical Cancer Research|2012Cited by 124
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan‐Dagliyan, Channing J. Der, J. Nathaniel Diehl et al.|Cell Reports|2020Cited by 108
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin Lin, Kris C. Wood, Justine C. Rutter et al.|Nature Cancer|2022Cited by 42
Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell CarcinomaSehrish Javaid, Adrienne D. Cox, Antje Schaefer et al.|Molecular Cancer Therapeutics|2022Cited by 18